Safety Concerns Make Bayer Unblind Prostate Cancer Trial of Xofigo Combination
News
An Independent Data Monitoring Committee has asked Bayer to unblind a Phase 3 clinical trial of a Xofigo (radium-223)-based therapy for prostate cancer after data indicated more bone fractures in ... Read more